Condition: Advanced or Metastatic Solid Tumors · Sponsor: Hanmi Pharmaceutical Company Limited
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation part is planned to establish the MTD or RD for Dose-Expansion part, while Dose-Expansion part is designed to assess potential efficacy of BH3120, as a single agent and in combination with pembrolizumab, when administered at the RD to subjects in indication-specific expansion cohorts.
This description comes directly from the study's public registry record.
Young Su (Bobby) Noh · 82-2-410-9277 · 63forever@hanmi.co.kr
Always discuss trial participation with your own doctor first.
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| The START Center for Cancer Care - Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center | Cincinnati, Ohio, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Withdrawn |
| Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cencer Center | San Antonio, Texas, United States | Recruiting |
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06234397